Oncimmune LLC announced the release of EarlyCDT-Lung, a simple blood test with the ability to detect the earliest stages of lung cancer when treatment can be most successful. Categorized as a high-complexity test under CLIA guidelines, the test is performed exclusively at Oncimmune's CLIA registered laboratory where multiple high-precision liquid handling robots and other instrumentation are used.

EarlyCDT-Lung measures a panel of six autoantibodies each selected for their involvement in the development of lung cancer. The test detects the body's immune response in the form of antibodies to antigens, which are produced by solid-tumor cancer cells. In healthy individuals, the immune system does not produce antibodies against normal tissue antigens. When cancer develops, cancer cells produce antigens that are abnormal or in some way modified from those found in normal tissue. The immune system detects these antigens and reacts by producing an abundance of autoantibodies that circulate in the bloodstream. As these autoantibodies form and circulate in the body during stages I and II, the earliest stages of lung cancer, their measurement signifies the presence of cancerous cells, indicating that a tumor exists. Used in conjunction with diagnostic imaging, EarlyCDT-Lung has the potential to identify lung cancer at a very early stage, when treatment can be most successful. The test is primarily recommended for individuals who are at higher risk of lung cancer, such as long-term smokers, ex-smokers and those exposed to environmental factors such as asbestos, radon and/or radioactive substances.

For more information, you may download a brochure here (pdf file).